Raymond James Financial’s Trevi Therapeutics TRVI Stock Holding History

Raymond James Financial’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.1M	Sell	1,687,977 -78,986	-4%	-$884K	0.01%	1467
2025 Q4	$22.1M	Buy	1,766,963 +355,926	+25%	+$4.11M	0.01%	1371
2025 Q3	$12.9M	Buy	1,411,037 +334,354	+31%	+$2.51M	﹤0.01%	1729
2025 Q2	$5.89M	Buy	1,076,683 +567,304	+111%	+$3.53M	﹤0.01%	2263
2025 Q1	$3.2M	Buy	509,379 +497,379	+4,145%	+$2.37M	﹤0.01%	2652
2024 Q4	$49.4K	Buy	+12,000	New	+$38.4K	﹤0.01%	4610

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Raymond James Financial's TRVI Position: Q1 2026 in Review

Raymond James Financial reduced its Trevi Therapeutics (TRVI) stake by 4.5% in Q1 2026, selling an estimated $884K and leaving 1,687,977 shares worth $20.1M. The position accounts for 0.01% of the portfolio, ranked #1467.

Raymond James Financial first reported a position in TRVI in Q4 2024 and has held it in 6 quarters since. The position peaked at $22.1M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Raymond James Financial held 1,687,977 shares of Trevi Therapeutics worth $20.1M as of Q1 2026.
Raymond James Financial sold 78,986 Trevi Therapeutics shares in Q1 2026, an estimated $884K.
Trevi Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1467 holding.
Raymond James Financial first reported a position in Trevi Therapeutics in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Trevi Therapeutics position peaked at $22.1M in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.